Lercanid-BP

Lercanidipinum

Each film-coated tablet contains lercanidipine hydrochloride 20 mg (as lercanidipine hydrochloride hemihydrate). Excipient with known effect: lactose monohydrate, sunset yellow.

Each film-coated tablet contains lercanidipine hydrochloride 10 mg (as lercanidipine hydrochloride hemihydrate). Excipient with known effect: lactose monohydrate.

Indication: Lercanid-BP is indicated in adults for treatment of mild to moderate essential hypertension.

Contraindications (SmPC sec. 4.3): 4.3 Contraindications − Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. − Patients with left ventricular outflow obstruction. − Untreated congestive heart failure. − Unstable angina pectoris or within one month of a myocardial infarction. − Severe hepatic impairment. − Severe renal impairment (creatinine clearance < 30 ml/min), including patients undergoing dialysis. − Concomitant administration with: potent CYP3A4 inhibitors (see section 4.5), ciclosporin (see section 4.5), grapefruit or grapefruit juice (see section 4.5).

Special warnings and precautions (SmPC sec. 4.4, excerpt): 4.4 Special warnings and precautions for use Sick sinus syndrome Lercanidipine should be administered with caution in patients with sick sinus syndrome (if the patient does not have a pacemaker). Left ventricular dysfunction Although controlled haemodynamic studies have not shown impairment of ventricular function, caution is required in patients with left ventricular dysfunction. Myocardial ischaemia It has been suggested that the use of certain short-acting dihydropyridines may be associated with increased cardiovascular risk in patients with myocardial ischaemia. Although lercanidipine is a long-acting substance, caution is recommended in such patients. Precordial pain or angina pectoris has rarely been reported with the use of certain dihydropyridines. In patients diagnosed with angina pectoris, very rare reports have described an increase in the frequency […]